1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

0R1F.IL
Bristol-Myers Squibb CompanyGB flagInternational Order Book
65.75
USD
+1.90
- -
134.31BMarket Cap
Bristol-Myers Squibb Company
0R1F.IL
(International Order Book)

Recent

price

65.75

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
11.37
12.5
10.55
9.97
9.58
9.93
11.63
12.63
13.82
15.33
18.83
21.54
21.67
21.75
23.83
23.69
24.13
Revenue per Share
1.81
2.18
1.17
1.56
1.21
0.94
2.67
0.61
3.01
2.02
-3.99
3.25
2.97
3.88
-4.41
3.47
4.55
Basic EPS, GAAP
2.37
2.63
3.83
1.83
1.58
1.26
1.83
3.21
4.33
4.82
6.22
7.53
6.13
6.7
7.49
6.96
6.27
Free Cash Flow per Basic Share
1.29
1.33
1.37
1.4
1.45
1.49
1.52
1.57
1.6
1.57
1.8
2.04
2.18
2.29
2.4
2.48
2.5
Dividend per Share
9.25
9.47
8.36
9.23
8.98
8.59
9.72
7.23
8.64
23.16
17.03
16.7
14.97
14.56
8.05
9.07
10.93
Book Value per Share
4.18
4.3
-1.71
3.5
3.67
3.59
4.76
2.26
3.94
-15.65
-16.29
-12.69
-12.74
-9.51
-14.31
-11.12
-8.35
Tangible Book Value per Share
1,713
1,700
1,670
1,644
1,657
1,667
1,671
1,645
1,633
1,705
2,258
2,153
2,130
2,069
2,027
2,034
2,039
Basic Weighted Avg Shares
19,484
21,244
17,621
16,385
15,879
16,560
19,427
20,776
22,561
26,145
42,518
46,385
46,159
45,006
48,300
48,195
49,187
Sales/Revenue/Turnover
30.54
31.24
22.31
17.89
10.79
10.45
23.36
16.59
22.79
16.5
5.15
18.4
19.72
18.21
12.19
28.48
28.14
Operating Margin (%)
607
628
681
763
467
376
382
789
637
1,746
10,380
10,686
10,276
9,760
9,600
4,011
3,176
Depreciation Expense
3,102
3,709
1,960
2,563
2,004
1,565
4,457
1,007
4,920
3,439
-9,015
6,994
6,327
8,025
-8,948
7,054
9,282
Net Income, GAAP
25.66
24.65
- -
10.76
14.78
21.47
23.8
81
17.11
30.45
- -
13.39
17.74
4.74
- -
24.36
22.12
Effective Tax Rate (%)
15.92
17.46
11.12
15.64
12.62
9.45
22.94
4.85
21.81
13.15
-21.2
15.08
13.71
17.83
-18.53
14.64
18.87
Profit Margin (%)
6,534
7,538
1,242
6,476
6,147
2,398
4,863
5,291
7,062
11,050
11,112
11,394
5,383
9,508
6,006
5,973
9,920
Working Capital
5,328
5,376
6,568
7,981
7,242
6,550
5,716
6,975
5,646
44,059
49,169
40,479
36,317
38,183
48,973
44,676
43,819
LT Debt
15,638
15,867
13,638
15,236
14,983
14,424
16,347
11,847
14,127
51,698
37,882
36,006
31,118
29,485
16,388
18,506
22,319
Total Equity
20.83
23.52
- -
11.69
6.26
6.1
15.51
3.06
20.59
4.92
- -
8.64
9.75
10.86
- -
15.61
15.9
Return on Invested Capital (%)
8.52
10.68
- -
12.21
9.28
7.48
20.53
5.02
24.44
6.42
- -
9.5
9.54
12.78
- -
12.73
15.67
Return on Capital (%)
20.3
23.42
13.25
17.81
13.36
10.75
29.28
7.21
38.18
10.48
-20.16
18.96
18.88
26.53
-39.1
40.53
46.7
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2,463
2,506
1,234
LT Borrowings
42,850
42,152
42,093
LT Finance Leases
1,826
1,770
1,726
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,036
2,042
2,042
Market Capitalization
110,541
122,708
119,033

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
29,390
27,208
28,579
Cash, Cash Equivalents & STI
10,673
10,486
11,067
Accounts Receivable, Net
9,592
7,947
9,077
Inventories
2,690
2,756
2,737
Total Current Liabilities
23,417
19,158
18,659
Payables & Accruals
6,321
6,936
6,839
ST Debt
2,463
2,506
1,234
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.9%
-11.06%
12.92%
Free Cash Flow
24.39%
0.97%
-6.81%
Net Income, GAAP
-44.69%
-110.12%
-178.83%
Sales/Revenue/Turnover
12.46%
2.64%
-0.22%
Total Cash Common Dividend
8.2%
4.38%
3.74%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11,865
12,201
11,892
12,342
48,300
2025
11,201
12,269
12,222
12,503
48,195
2026
11,489
12,973
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-5.89
0.83
0.6
0.04
-4.41
2025
1.21
0.64
- -
0.53
3.47
2026
1.31
1.62
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.6
0.6
0.6
0.6
2.4
2025
0.62
0.62
- -
0.62
2.48
2026
0.63
0.63
- -
- -
- -
Similar Companies
GABY Inc. (GABLF)
Trident Lifeline Limited (TLL.BO)
PharmaResearch Co., Ltd. (214450.KQ)
JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. (JSP.BK)
Tong Ren Tang Technologies Co. Ltd. (TGRNF)
Ishita Drugs and Industries Limited (ISHITADR.BO)
Business
Bristol-Myers Squibb Company is a multinational biopharmaceutical company that discovers, develops, manufactures, and markets innovative medicines across oncology, hematology, immunology, cardiovascular, fibrosis, and central nervous system therapeutic areas; the company delivers branded biologics and small-molecule therapies through prescription medicines, biosimilars, and research collaboration programs; it also provides patient support services, diagnostic and companion diagnostic tools, and clinical development services through strategic partnerships and contract research arrangements. The company's core products and services span oncology therapies (including tumor-targeted biologics and immuno-oncology agents), cardiovascular and metabolic drugs, immunology and inflammation treatments, neuroscience products, and rare disease programs; it licenses, co-develops, and commercializes products with external partners, and maintains a robust portfolio of marketed medicines, product candidates in clinical development, and pipeline acceleration initiatives. Latest major company changes include strategic alliances and collaborations to expand its oncology and immunology pipelines; acquisitions and divestitures to optimize portfolio fit and cash generation; launches and regulatory approvals of new therapies across key markets; organizational realignments to streamline operations and enhance commercialization capabilities; ongoing geographic expansions and manufacturing network optimization; and significant investments in research, digital health initiatives, and companion diagnostics. Additional context: operates globally with a diversified business model spanning research, development, manufacturing, and commercialization of pharmaceutical products; targets healthcare providers, patients, and payers across major regions including North America, Europe, Asia-Pacific, and emerging markets; founded in 1887 and headquartered in New York, New York, USA; maintains subsidiaries and strategic partnerships to advance bioscience capabilities and clinical programs.